The present authors carried out an open up-label pilot study that administered psilocybin to 15 treatment-resistant tobacco/nicotine-dependent smokers, within the context of cognitive behavioral therapy for using tobacco cessation [fifty eight]. Individuals had been administered ~0.29 mg/kg oral psi